The Risk of Acute Kidney Injury in Hepatitis B Virus-Related Acute on Chronic Liver Failure with Tenofovir Treatment

Table 1

Baseline characteristics of study population.

Variable	Unmatched			Matched
	ETV group ()	TDF group ()	value	ETV group ()	TDF group ()	value
Age (years)			0.266			0.631
Male, (%)	42 (75.00%)	29 (74.36%)	0.944	30 (76.92%)	29 (74.36%)	0.792
Ascites, (%)	44 (78.57%)	31 (79.49%)	0.914	29 (74.36%)	31 (79.49%)	0.591
HE, (%)	9 (16.07%)	5 (12.82%)	0.884	7 (17.95%)	5 (12.82%)	0.530
Cirrhosis, (%)	39 (69.62%)	29 (74.36%)	0.787	26 (66.67%)	29 (74.36%)	0.456
TBIL (mmol/L)			0.396			0.612
ALT (U/L)			0.071			0.354
AST (U/L)			0.031			0.200
Albumin (g/L)	30.05 (27.85-32.80)	30.00 (27.90-34.00)	0.934	29.80 (27.40-33.30)	30.00 (27.90-34.00)	0.768
INR			0.249			0.864
BUN (mmol/L)			0.052			0.203
sCr (μmol/L)			0.474			0.633
Cystatin C (mg/L)			0.128			0.301
GFR (mL/min)			0.392			0.650
HBsAglog10 (ng/mL)			0.595			0.243
HBeAg-positive, (%)	26 (46.43%)	22 (52.79%)	0.454	19 (48.72%)	22 (52.79%)	0.496
HBVDNAlog10 (IU/mL)			0.560			0.903
Na (mmol/L)			0.007			0.058
WBC (×10^9/L)			0.247			0.510
HGB (g/L)	119.07 (102.25-136.50)	132.67 (119.00-147.00)	0.011	124.00 (111.00-143.00)	132.67 (119.00-147.00)	0.147
Platelets (×10^9/L)			0.303			0.820
CTP score			0.766			0.694
MELD score			0.139			0.928
MELD-Na score			0.047			0.593
CLIF-SOFA score			0.603			0.852
Diabetes, (%)	8 (14.29%)	3 (7.70%)	0.508	5 (12.82%)	3 (7.70%)	0.709
Hypertension, (%)	7 (12.50%)	2 (5.13%)	0.395	4 (10.26%)	2 (5.13%)	0.671

HE: hepatic encephalopathy; TBIL: total bilirubin; ALT: alanine aminotransferase; AST: aspartate transaminase; INR: international normalized ratio; BUN: blood urea nitrogen; sCr: serum creatinine; GFR: glomerular filtration rate; HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B e antigen; WBC: white blood cell; HGB: hemoglobin; CTP: Child-Turcotte-Pugh; MELD: model for end-stage liver disease; CLIF-SOFA: chronic liver failure-sequential organ failure assessment.